89 results
Page 4 of 5
8-K
EX-99.1
y0pj7dt9
11 Mar 19
Regulation FD Disclosure
2:51pm
424B5
ekbjh2jiqmdc2udhy
21 Feb 19
Prospectus supplement for primary offering
9:24pm
424B5
06h7fawz6k74 2ve
21 Feb 19
Prospectus supplement for primary offering
9:22pm
8-K
EX-1.1
6u9ltf80vxl9hwgge
21 Feb 19
Ovid Therapeutics Announces Pricing of $30 Million of Securities in Concurrent Public Offerings of Common and Preferred Stock
4:53pm
8-K
EX-1.2
lq3lnr7yf
21 Feb 19
Ovid Therapeutics Announces Pricing of $30 Million of Securities in Concurrent Public Offerings of Common and Preferred Stock
4:53pm
424B5
dvoi 1b5u
19 Feb 19
Prospectus supplement for primary offering
4:06pm
424B5
6crz6s u12q8k4
19 Feb 19
Prospectus supplement for primary offering
4:04pm
8-K
EX-99.1
yp4 fbu1yk6
19 Feb 19
Results of Operations and Financial Condition
4:01pm
8-K
EX-99.1
r68yg8fw
7 Jan 19
Regulation FD Disclosure
6:31am
8-K
EX-99.1
1jinkuz 15il
6 Dec 18
Ovid Therapeutics Announces Plans to Move into a Phase 3 Trial in Pediatric Patients Based on End-of-Phase 2 Meeting for OV101 in Angelman Syndrome
8:05am
8-K
EX-99.2
b979htsleczp6z 3bhr
25 Oct 18
Regulation FD Disclosure
10:25am
8-K
EX-99.1
p73tjyh
25 Oct 18
Regulation FD Disclosure
10:25am
8-K
EX-99.1
z86r4 j9u6n
9 Aug 18
Ovid Therapeutics Reports Second Quarter 2018 Financial Results and Highlights Recent Clinical Progress
12:00am
8-K
EX-99.1
o9p82ugv
6 Aug 18
Other Events
4:31pm
S-3
EX-1.2
98ab8
1 Jun 18
Shelf registration
5:14pm